ResearchMoz
presents this most up-to-date research on Hepatitis C Market &
Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical
Trials - Global.
Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.
This is 3rd edition report on Hepatitis C Drugs Industry. Report titled “Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.
1. Hepatitis C Drugs Market & Forecast (Chapter 2)
2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4)
4. Hepatitis C Deals & Acquisitions (Chapter 5)
5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6)
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=423184
Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)
1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
5. Olysio
6. Sovaldi/Harvoni
7. HCV Franchise
8. Viekira Pak
Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)
1. Drug A (Merck & Co. Inc.)
2. Drug B (Merck & Co. Inc.)
3. Drug C (Bristol-Myers Squibb)
Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5)
1. AbbVie
2. Bristol-Myers Squibb (BMS)
3. Gilead Sciences
4. Merck & Co. Inc.
5. Tibotec/Janssen Therapeutics
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=423184
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.
This is 3rd edition report on Hepatitis C Drugs Industry. Report titled “Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.
1. Hepatitis C Drugs Market & Forecast (Chapter 2)
2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4)
4. Hepatitis C Deals & Acquisitions (Chapter 5)
5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6)
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=423184
Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)
1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
5. Olysio
6. Sovaldi/Harvoni
7. HCV Franchise
8. Viekira Pak
Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)
1. Drug A (Merck & Co. Inc.)
2. Drug B (Merck & Co. Inc.)
3. Drug C (Bristol-Myers Squibb)
Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5)
1. AbbVie
2. Bristol-Myers Squibb (BMS)
3. Gilead Sciences
4. Merck & Co. Inc.
5. Tibotec/Janssen Therapeutics
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=423184
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
No comments:
Post a Comment